D&A at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept amrx:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s D&A?
- Amneal Pharmaceuticals, Inc. (AMRX) reported D&A of $43.19M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s D&A changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s D&A decreased by 28.2% year-over-year, from $60.16M to $43.19M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s D&A?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s D&A has grown at a -1.1% compound annual growth rate (CAGR), from $233.41M to $223.57M.
- What does D&A mean?
- This represents the non-cash expense recognized over the useful life of tangible and intangible assets. It reflects the systematic allocation of asset costs to the periods in which they contribute to revenue generation.